Literature DB >> 15707619

Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease.

M Garcia-Alloza1, F J Gil-Bea, M Diez-Ariza, C P L-H Chen, P T Francis, B Lasheras, M J Ramirez.   

Abstract

Neuropsychiatric symptoms seen in Alzheimer's disease (AD) are not simply a consequence of neurodegeneration, but probably result from differential neurotransmitter alterations, which some patients are more at risk of than others. Therefore, the hypothesis of this study is that an imbalance between the cholinergic and serotonergic systems is related to cognitive symptoms and psychological syndromes of dementia (BPSD) in patients with AD. Cholinergic and serotonergic functions were assessed in post-mortem frontal and temporal cortex from 22 AD patients who had been prospectively assessed with the Mini-Mental State examination (MMSE) for cognitive impairment and with the Present Behavioral Examination (PBE) for BPSD including aggressive behavior, overactivity, depression and psychosis. Not only cholinergic deficits, but also the cholinacetyltransferase/serotonin ratio significantly correlated with final MMSE score both in frontal and temporal cortex. In addition, decreases in cholinergic function correlated with the aggressive behavior factor, supporting a dual role for the cholinergic system in cognitive and non-cognitive disturbances associated to AD. The serotonergic system showed a significant correlation with overactivity and psychosis. The ratio of serotonin to acetylcholinesterase levels was also correlated with the psychotic factor at least in women. It is concluded that an imbalance between cholinergic-serotonergic systems may be responsible for the cognitive impairment associated to AD. Moreover, the major findings of this study are the relationships between neurochemical markers of both cholinergic and serotonergic systems and non-cognitive behavioral disturbances in patients with dementia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15707619     DOI: 10.1016/j.neuropsychologia.2004.06.007

Source DB:  PubMed          Journal:  Neuropsychologia        ISSN: 0028-3932            Impact factor:   3.139


  59 in total

1.  Citalopram for agitation in Alzheimer's disease: design and methods.

Authors:  Lea T Drye; Zahinoor Ismail; Anton P Porsteinsson; Paul B Rosenberg; Daniel Weintraub; Christopher Marano; Gregory Pelton; Constantine Frangakis; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; D P Devanand; Jerome Yesavage; Jacobo E Mintzer; Lon S Schneider; Bruce G Pollock; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2012-02-01       Impact factor: 21.566

Review 2.  Non-pharmacological Management of Behavioral Symptoms in Frontotemporal and Other Dementias.

Authors:  Cynthia Barton; Robin Ketelle; Jennifer Merrilees; Bruce Miller
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

3.  Cholinergic blockade under working memory demands encountered by increased rehearsal strategies: evidence from fMRI in healthy subjects.

Authors:  Bianca Voss; Renate Thienel; Martina Reske; Thilo Kellermann; Abigail J Sheldrick; Sarah Halfter; Katrin Radenbach; Nadim J Shah; Ute Habel; Tilo T J Kircher
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-10-18       Impact factor: 5.270

4.  Effects of dietary supplementation with N-acetyl cysteine, acetyl-L-carnitine and S-adenosyl methionine on cognitive performance and aggression in normal mice and mice expressing human ApoE4.

Authors:  Amy Chan; Thomas B Shea
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

5.  Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease.

Authors:  Robyn Carson; David Craig; Dominic Hart; Stephen Todd; Bernadette McGuinness; Janet A Johnston; Francis A O'Neill; Craig W Ritchie; A Peter Passmore
Journal:  Neuromolecular Med       Date:  2008-08-12       Impact factor: 3.843

6.  Treatments for Depression in Older Persons with Dementia.

Authors:  Zvi D Gellis; Kimberly P McClive-Reed; Ellen Brown
Journal:  Ann Longterm Care       Date:  2009-02-02

Review 7.  Neuropsychiatric symptoms in Alzheimer's disease: What might be associated brain circuits?

Authors:  Paul B Rosenberg; Milap A Nowrangi; Constantine G Lyketsos
Journal:  Mol Aspects Med       Date:  2015-06-03

8.  Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease.

Authors:  Maja Mustapic; Paola Presecki; Nela Pivac; Ninoslav Mimica; Patrick R Hof; Goran Simic; Vera Folnegovic-Smalc; Dorotea Muck-Seler
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-02-13       Impact factor: 5.067

Review 9.  Serotonergic system, cognition, and BPSD in Alzheimer's disease.

Authors:  Saikat Chakraborty; Jack C Lennon; Sridhar A Malkaram; Yan Zeng; Daniel W Fisher; Hongxin Dong
Journal:  Neurosci Lett       Date:  2019-04-01       Impact factor: 3.046

Review 10.  Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status.

Authors:  Maria J Ramirez; Mitchell K P Lai; Rosa M Tordera; Paul T Francis
Journal:  Drugs       Date:  2014-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.